Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis
Publisher Name » GBI Research
Published Date » 2010-02-15
No. Of Pages » 77
GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis”. It is an essential source of information and analysis on global stem cell research and development. This pharmaceutical and healthcare report identifies the key trends shaping and driving stem cell research and development. The report analyses investment decisions within the stem cell research market by providing information on pipelines, federal spending, investor perspectives, regulatory environment, competitive landscape and market potential. The study also provides insight on the prevalent competitive landscape and the emerging players expected to significantly shift the market positioning. Most importantly, the report provides valuable insight on the pipeline products within the global stem cell industry.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes:
- Unmet needs and opportunity analysis for therapies that are currently in pipeline.
- Market characterization including market sizing, technology adoption framework and business models for the stem cell market.
- A cross-country analysis for regulatory framework, investments, research clusters and support including the US (United States), the UK (United Kingdom), Germany, France, Japan, China, India, Singapore, Canada and Australia
- In-depth information and analysis on the pipeline products expected to bring a shift in the market positions of the leading manufacturers.
- Analysis and review of the key events and milestones that will impact the future of the global stem cell market. Each trend independently researched to provide qualitative analysis of what the implications on sectors are, and how companies are responding to these trends.
- Insightful review of key industry drivers, restraints and challenges which are likely to impact the global stem cell research and development in the long run.
- Information on the leading market players and the prevailing competitive landscape. Key companies covered include Osiris Therapeutics, Aastrom Biosciences, Cytori Therapeutics, Pluristem Therapeutics and Geron.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying companies with the most robust pipelines
- Develop business strategies by understanding the trends shaping and driving stem cell research and development.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the stem cell market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
- What’s the next big thing in the stem cell research and development landscape? - Identify, understand and capitalize.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 GBI Research Report Guidance 7
3 Market Overview 9
3.1 Stem Cell Research An Introduction 9
3.2 Types of Stem Cell Research 9
3.3 Unmet Needs 10
3.4 Applications of Stem Cell Research 14
4 Market Characterization 16
4.1 Stem Cell Market An Introduction 16
4.2 Market Sizing 16
4.3 Therapy cost 18
4.4 Technology Adoption Framework 19
4.5 Types of Business Models 19
4.6 Market Drivers 21
4.6.1 Supporting Political Environment on Embryonic Stem Cell Research will Advance the Stem Cell Industry to Prosper in the United States 21
4.6.2 Limited Availability of Treatments to Treat Certain Disease Conditions Increases Market Opportunity for Stem Cell Research 22
4.7 Market Barriers & Challenges 23
4.7.1 Stem Cell Research and Development is an expensive process which requires considerable funding to be operational. 23
4.7.2 Availability of Adequate Reimbursements are Unclear and leads to a conundrum 23
4.7.3 Ethical, legal and social issues persists and acts as a challenge 24
4.7.4 Identifying, recruiting and retaining the best scientific talents is an intractable process for stem cell research based companies 25
4.8 Stem Cell Research and Development - Market Trends 25
4.8.1 Booming Stem Cell Tourism is a Potential Opportunity for Countries to Attract Investments. 25
4.8.2 ASLAP Analysis of Stem Cell Tourism 26
4.8.3 Federal Funding Support Improves the Stem Cell Research Environment 27
4.8.4 Increasing Entry of Pharmaceutical Companies Boosts Stem Cell Research & Development 28
4.8.5 PESTLE Analysis 30
4.8.6 SWOT Analysis of Stem Cell Research & Development 31
4.9 Industry Analysis 33
5 Stem Cell Research and Development - Pipeline Analysis 35
5.1 Pipeline by Various Phases 35
5.2 Phase III Pipeline Analysis 35
5.3 Phase II Pipeline Analysis 37
5.4 Preclinical and Phase 1 Pipeline 39
6 Stem Cell Research and Development - Investment Trends 40
6.1 Investors Perspective on Stem Cell Research 40
6.2 NIH spending in Stem Cell Research and Development is Increasing and is Supportive 42
6.2.1 NIH Spending by Stem Cell Research Type 43
6.2.2 High Budget Projects Funded by NIH 44
6.3 States Funding on Stem Cell Research in the US is in Reconsideration. 45
6.4 R&D Spending by Stem Cell Research Companies 46
7 Stem Cell Research and Development - Geographical Trends 47
7.1 Stem Cell Companies by Geographic Regions 47
7.2 The United States 48
7.3 United Kingdom 49
7.4 China 50
7.5 Netherlands 51
7.6 Singapore 52
7.7 South Korea 53
7.8 Japan 54
7.9 India 55
7.10 Sweden 56
7.11 Denmark 57
7.12 France 58
7.13 Germany 59
7.14 Israel 60
7.15 Australia 61
7.16 Canada 62
7.17 Czech Republic 63
8 Stem Cell Research and Development - Mergers and Acquisitions 64
9 Stem Cell Research and Development - Competitive Structure 65
9.1 Stem Cell Companies by Therapy Areas 65
9.2 Stem Cell Companies by Stem Cell Types 66
10 Stem Cell Research and Development - Company Profiles 67
10.1 Aastrom Biosciences 67
10.2 Osiris Therapeutics 67
10.3 Bioheart 68
10.4 Aldagen 68
10.5 Mesoblast 69
10.6 Geron 69
10.7 Advanced Cell Technology 70
10.8 Cytori Therapeutics 70
10.9 Pluristem Therapeutics 71
10.10 Medistem 71
10.11 Neostem 72
11 Stem Cell Research and Development - Conclusion 73
12 Appendix 74
12.1 Market Definitions 74
12.2 Key Support Data 74
12.3 Abbreviations 74
12.4 Methodology 74
12.4.1 Coverage 75
12.4.2 Secondary Research 75
12.4.3 Primary Research 76
12.4.4 Expert Panels 76
12.5 Contact Us 76
12.6 Disclaimer 76
Table 1: Disease Conditions and Population in US 18
Table 2: Preferred Countries for Stem Cell Tourism 25
Table 3: Pharmaceutical Companies Partnership Environment 29
Table 4: Phase III Pipeline 35
Table 5: Phase II Pipeline 37
Table 6: Preclinical and Phase 1 Pipelines 39
Table 7: NIH Spending 42
Table 8: Spending of States in US on Stem Cell Research 45
Table 9: Mergers and Acquisitions in Stem Cell Research 64
Table 10: Aastrom Biosciences 67
Table 11: Osiris Therapeutics 67
Table 12: BioHeart 68
Table 13: Aldagen 68
Table 14: Mesoblast 69
Table 15: Geron 69
Table 16: Advanced Cell Technology 70
Table 17: Cytori Therapeutics 70
Table 18: Pluristem Therapeutics 71
Table 19: Medistem 71
Table 20: Neostem 72
Figure 1: Stem Cell Research and Development Segmentation 9
Figure 2: Stem Cells Interaction Framework 11
Figure 3: Cells Models Present and the Future 12
Figure 4: Unmet Need Vs Time to Market 13
Figure 5: Adult Stem Cells Applications 14
Figure 6: Technology Adoption Framework 19
Figure 7: Business Models in Stem Cell Industry 20
Figure 8: Political Environnent Impact Analysis 21
Figure 9: Treatment Availability Impact Analysis 22
Figure 10: Cost of Research Impact Analysis 23
Figure 11: Reimbursements Impact Analysis 23
Figure 12: Ethical, legal and Social Issues Impact Analysis 24
Figure 13: Human Resources Impact Analysis 25
Figure 14: ASLAP Analysis of Stem Cell Tourism 26
Figure 15: Stem Cell Research- Federal Funding Trend 27
Figure 16: PESTLE Analysis of Stem Cell Research 30
Figure 17: SWOT Analysis of Stem Cell Research and Development 31
Figure 18: SWOT Analysis of Stem Cell Research and Development Impact Grid 32
Figure 19: Five Force Analysis 33
Figure 20: Stem Cell Development Pipeline by Clinical Trial Phase 35
Figure 21: VCs Perspective on Stem Cell Research 40
Figure 22: VCs Perspective on Stem Cell Research Impact Analysis 41
Figure 23: NIH Spending by Stem cell Research Type 43
Figure 24: High Budget Projects Funded by NIH 44
Figure 25: R&D Spending by Public Companies 46
Figure 26: Stem Cell Companies by Geographic Regions 47
Figure 27: Country Analysis United States 48
Figure 28: Country Analysis United Kingdom 49
Figure 29: Country Analysis China 50
Figure 30: Country Analysis Netherlands 51
Figure 31: Country Analysis Singapore 52
Figure 32: Country Analysis South Korea 53
Figure 33: Country Analysis Japan 54
Figure 34: Country Analysis India 55
Figure 35: Country Analysis Sweden 56
Figure 36: Country Analysis Denmark 57
Figure 37: Country Analysis France 58
Figure 38: Country Analysis Germany 59
Figure 39: Country Analysis Israel 60
Figure 40: Country Analysis Australia 61
Figure 41: Country Analysis Canada 62
Figure 42: Country Analysis Czech Republic 63
Figure 43: Mergers and Acquisitions Year wise Analysis 64
Figure 44: Stem Cell Companies by Therapy Areas 65
Figure 45: Stem Cell Companies by Stem Cell Types 66
Figure 46: GBI Research Methodology 75
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 GBI Research Report Guidance 7
3 Market Overview 9
3.1 Stem Cell Research An Introduction 9
3.2 Types of Stem Cell Research 9
3.3 Unmet Needs 10
3.4 Applications of Stem Cell Research 14
4 Market Characterization 16
4.1 Stem Cell Market An Introduction 16
4.2 Market Sizing 16
4.3 Therapy cost 18
4.4 Technology Adoption Framework 19
4.5 Types of Business Models 19
4.6 Market Drivers 21
4.6.1 Supporting Political Environment on Embryonic Stem Cell Research will Advance the Stem Cell Industry to Prosper in the United States 21
4.6.2 Limited Availability of Treatments to Treat Certain Disease Conditions Increases Market Opportunity for Stem Cell Research 22
4.7 Market Barriers & Challenges 23
4.7.1 Stem Cell Research and Development is an expensive process which requires considerable funding to be operational. 23
4.7.2 Availability of Adequate Reimbursements are Unclear and leads to a conundrum 23
4.7.3 Ethical, legal and social issues persists and acts as a challenge 24
4.7.4 Identifying, recruiting and retaining the best scientific talents is an intractable process for stem cell research based companies 25
4.8 Stem Cell Research and Development - Market Trends 25
4.8.1 Booming Stem Cell Tourism is a Potential Opportunity for Countries to Attract Investments. 25
4.8.2 ASLAP Analysis of Stem Cell Tourism 26
4.8.3 Federal Funding Support Improves the Stem Cell Research Environment 27
4.8.4 Increasing Entry of Pharmaceutical Companies Boosts Stem Cell Research & Development 28
4.8.5 PESTLE Analysis 30
4.8.6 SWOT Analysis of Stem Cell Research & Development 31
4.9 Industry Analysis 33
5 Stem Cell Research and Development - Pipeline Analysis 35
5.1 Pipeline by Various Phases 35
5.2 Phase III Pipeline Analysis 35
5.3 Phase II Pipeline Analysis 37
5.4 Preclinical and Phase 1 Pipeline 39
6 Stem Cell Research and Development - Investment Trends 40
6.1 Investors Perspective on Stem Cell Research 40
6.2 NIH spending in Stem Cell Research and Development is Increasing and is Supportive 42
6.2.1 NIH Spending by Stem Cell Research Type 43
6.2.2 High Budget Projects Funded by NIH 44
6.3 States Funding on Stem Cell Research in the US is in Reconsideration. 45
6.4 R&D Spending by Stem Cell Research Companies 46
7 Stem Cell Research and Development - Geographical Trends 47
7.1 Stem Cell Companies by Geographic Regions 47
7.2 The United States 48
7.3 United Kingdom 49
7.4 China 50
7.5 Netherlands 51
7.6 Singapore 52
7.7 South Korea 53
7.8 Japan 54
7.9 India 55
7.10 Sweden 56
7.11 Denmark 57
7.12 France 58
7.13 Germany 59
7.14 Israel 60
7.15 Australia 61
7.16 Canada 62
7.17 Czech Republic 63
8 Stem Cell Research and Development - Mergers and Acquisitions 64
9 Stem Cell Research and Development - Competitive Structure 65
9.1 Stem Cell Companies by Therapy Areas 65
9.2 Stem Cell Companies by Stem Cell Types 66
10 Stem Cell Research and Development - Company Profiles 67
10.1 Aastrom Biosciences 67
10.2 Osiris Therapeutics 67
10.3 Bioheart 68
10.4 Aldagen 68
10.5 Mesoblast 69
10.6 Geron 69
10.7 Advanced Cell Technology 70
10.8 Cytori Therapeutics 70
10.9 Pluristem Therapeutics 71
10.10 Medistem 71
10.11 Neostem 72
11 Stem Cell Research and Development - Conclusion 73
12 Appendix 74
12.1 Market Definitions 74
12.2 Key Support Data 74
12.3 Abbreviations 74
12.4 Methodology 74
12.4.1 Coverage 75
12.4.2 Secondary Research 75
12.4.3 Primary Research 76
12.4.4 Expert Panels 76
12.5 Contact Us 76
12.6 Disclaimer 76
List of Tables
Table 1: Disease Conditions and Population in US 18
Table 2: Preferred Countries for Stem Cell Tourism 25
Table 3: Pharmaceutical Companies Partnership Environment 29
Table 4: Phase III Pipeline 35
Table 5: Phase II Pipeline 37
Table 6: Preclinical and Phase 1 Pipelines 39
Table 7: NIH Spending 42
Table 8: Spending of States in US on Stem Cell Research 45
Table 9: Mergers and Acquisitions in Stem Cell Research 64
Table 10: Aastrom Biosciences 67
Table 11: Osiris Therapeutics 67
Table 12: BioHeart 68
Table 13: Aldagen 68
Table 14: Mesoblast 69
Table 15: Geron 69
Table 16: Advanced Cell Technology 70
Table 17: Cytori Therapeutics 70
Table 18: Pluristem Therapeutics 71
Table 19: Medistem 71
Table 20: Neostem 72
List of Figures
Figure 1: Stem Cell Research and Development Segmentation 9
Figure 2: Stem Cells Interaction Framework 11
Figure 3: Cells Models Present and the Future 12
Figure 4: Unmet Need Vs Time to Market 13
Figure 5: Adult Stem Cells Applications 14
Figure 6: Technology Adoption Framework 19
Figure 7: Business Models in Stem Cell Industry 20
Figure 8: Political Environnent Impact Analysis 21
Figure 9: Treatment Availability Impact Analysis 22
Figure 10: Cost of Research Impact Analysis 23
Figure 11: Reimbursements Impact Analysis 23
Figure 12: Ethical, legal and Social Issues Impact Analysis 24
Figure 13: Human Resources Impact Analysis 25
Figure 14: ASLAP Analysis of Stem Cell Tourism 26
Figure 15: Stem Cell Research- Federal Funding Trend 27
Figure 16: PESTLE Analysis of Stem Cell Research 30
Figure 17: SWOT Analysis of Stem Cell Research and Development 31
Figure 18: SWOT Analysis of Stem Cell Research and Development Impact Grid 32
Figure 19: Five Force Analysis 33
Figure 20: Stem Cell Development Pipeline by Clinical Trial Phase 35
Figure 21: VCs Perspective on Stem Cell Research 40
Figure 22: VCs Perspective on Stem Cell Research Impact Analysis 41
Figure 23: NIH Spending by Stem cell Research Type 43
Figure 24: High Budget Projects Funded by NIH 44
Figure 25: R&D Spending by Public Companies 46
Figure 26: Stem Cell Companies by Geographic Regions 47
Figure 27: Country Analysis United States 48
Figure 28: Country Analysis United Kingdom 49
Figure 29: Country Analysis China 50
Figure 30: Country Analysis Netherlands 51
Figure 31: Country Analysis Singapore 52
Figure 32: Country Analysis South Korea 53
Figure 33: Country Analysis Japan 54
Figure 34: Country Analysis India 55
Figure 35: Country Analysis Sweden 56
Figure 36: Country Analysis Denmark 57
Figure 37: Country Analysis France 58
Figure 38: Country Analysis Germany 59
Figure 39: Country Analysis Israel 60
Figure 40: Country Analysis Australia 61
Figure 41: Country Analysis Canada 62
Figure 42: Country Analysis Czech Republic 63
Figure 43: Mergers and Acquisitions Year wise Analysis 64
Figure 44: Stem Cell Companies by Therapy Areas 65
Figure 45: Stem Cell Companies by Stem Cell Types 66
Figure 46: GBI Research Methodology 75
Upcoming Reports:
|
EPharmacies Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The global market for ePharmacies is projected to reach USD 51.75 billion by the end of 2017 owing to the increasing number of tech-savvy people and rising demand for prescription drugs. The ePharmacies meeting the regulatory standards set by the government and following ethical business practices are likely to emerge as safe, affordable, and accessible source of prescription drugs in the near future. The present scenario reflects higher penetration of the ePharmacy industry in developed countries as compared to the developing market. This is mainly because of the increasing use of...
|
|
Content Delivery Network (CDN) - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2018
By - Transparency Market Research
CDN stands for “Content Delivery Network.” This network delivers a variety of content mainly video to web browsers, set-top boxes, mobile devices and gaming consoles. It is the basic term in online video or streaming. In the system of distributed servers, the web content and webpages are delivered based on the geographic location of the user, a content delivery server and the origin of the webpage. This system is highly effective in enhancing bandwidth and thus it improves access to the data. CDN comprises of applications, web objects, downloadable data objects,...
|
|
Electrical Transmission & Distribution Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Increasing use of renewable energy sources, aging infrastructure, and rising demand for electricity are encouraging the need to improve transmission efficiency and energy security, thus contributing to the growth of electrical transmission and distribution market. This market is forecasted to reach the market value of $33.45 billion by the end of the year 2012 owing to the technological developments in transmission grid technology.
Most regions and countries are expected to experience strong growth in electric power transmission industry as governments of most countries are...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Share this report
Latest Reports
- The Future of the Haircare Market in Egypt to 2017
- The Future of the Haircare Market in Denmark to 2017
- Overview of international chemical market
- Russian market of microcredits and lending to SME in Russia
- Overview of furniture market
- The Future of the Haircare Market in Czech Republic to 2017
- LTE Strategy 2013 - 2018
- Natural And Synthetic (Ethoxyquin, BHA, BHT) Animal Feed Antioxidants Market For Swine, Poultry, Cattle And Aquaculture - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
- Seed Treatment Market (Insecticides, Fungicides, Other Chemical And Nonchemical Treatment) For Corn, Soybean, Wheat, Canola, Cotton And Others - Global Industry Analysis, Size, Share, Growth And Forecast, 2012 - 2018
- Fish Oil Market For Aquaculture, Direct Human Consumption, Hydrogenation And Industrial Applications - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
